emconcor chf 5 mg
merck ab (1) - bisoprololfumarat - tablett, filmdrasjert - 5 mg
emconcor chf 10 mg
merck ab (1) - bisoprololfumarat - tablett, filmdrasjert - 10 mg
lodoz 2.5 mg / 6.25 mg
merck ab (1) - bisoprololfumarat / hydroklortiazid - tablett, filmdrasjert - 2.5 mg / 6.25 mg
lodoz 5 mg / 6.25 mg
merck ab (1) - bisoprololfumarat / hydroklortiazid - tablett, filmdrasjert - 5 mg / 6.25 mg
stromolol 2.5 mg
aristo pharma gmbh - bisoprololfumarat - tablett, filmdrasjert - 2.5 mg
xtandi
astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
veltassa
vifor fresenius medical care renal pharma france - patriomer sorbitex kalsium - hyperkalemi - legemidler for behandling av hyperkalemi og hyperphosphatemia - veltassa er indisert for behandling av hyperkalemi hos voksne.
rimactazid 150 mg / 75 mg
sandoz - københavn - rifampicin / isoniazid - tablett, filmdrasjert - 150 mg / 75 mg
rimstar
sandoz - københavn - rifampicin / isoniazid / pyrazinamid / etambutolhydroklorid - tablett, filmdrasjert - 150 mg / 75 mg / 400 mg / 275 mg
namuscla
lupin europe gmbh - mexiletine hydrochloride - myotonic lidelser - hjertetapi - namuscla er indikert for symptomatisk behandling av myotonia hos voksne pasienter med ikke-dystrophic myotonic lidelser.